Early Intervention is Needed to Meet the Challenge of Immune-Related Adverse Events
source: pixabay.com

Early Intervention is Needed to Meet the Challenge of Immune-Related Adverse Events

  According to the American Cancer Society, there are approximately 1.7 million people in the U.S. diagnosed with cancer each year. About forty percent of these cases may be eligible…

Continue Reading Early Intervention is Needed to Meet the Challenge of Immune-Related Adverse Events
Recent Study Suggests Changes to Renal Cell Carcinoma Staging Classification
source: pixabay.com

Recent Study Suggests Changes to Renal Cell Carcinoma Staging Classification

According to a story from Medscape, a recent cohort study published in the journal Cancer has concluded that updates are needed to the staging classification currently in use for renal cell carcinoma…

Continue Reading Recent Study Suggests Changes to Renal Cell Carcinoma Staging Classification
Tailored EPOCH-R Treatment Benefits Adults with Burkitt Lymphoma, Says Study
stevepb / Pixabay

Tailored EPOCH-R Treatment Benefits Adults with Burkitt Lymphoma, Says Study

High dose-intensive chemotherapy regimens have been shown as effective for children with Burkitt lymphoma. However, the intensity often leads to discomfort, adverse reactions, and poor outcomes in adult patients, particularly…

Continue Reading Tailored EPOCH-R Treatment Benefits Adults with Burkitt Lymphoma, Says Study
Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma
mohamed_hassan / Pixabay

Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma

According to the ASCO Post, researchers have discovered genomic characteristics of smoldering multiple myeloma that can tell one's risk of progression to multiple myeloma. Dr. Mark Bustoros and his team…

Continue Reading Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma

CASI Pharmaceuticals Files CTA (IND) for Novel Multiple Myeloma Treatment

  According to a recent press release, biopharmaceutical company CASI Pharmaceuticals filed a Clinical Trial Application (CTA) (IND) in the United Kingdom. CASI Pharmaceuticals is hoping to test the safety…

Continue Reading CASI Pharmaceuticals Files CTA (IND) for Novel Multiple Myeloma Treatment
Keytruda Improves Progression-Free Survival for Advanced Colorectal Cancer Patients
source: pixabay.com

Keytruda Improves Progression-Free Survival for Advanced Colorectal Cancer Patients

  Findings of the interim analysis from KEYNOTE-177 were presented at the virtual scientific meeting of the American Society of Clinical Oncology (ASCO) held in May 2020. The lead author…

Continue Reading Keytruda Improves Progression-Free Survival for Advanced Colorectal Cancer Patients
Experimental Treatment for Neuroblastoma Earns Rare Pediatric Disease Designation
source: pixabay.com

Experimental Treatment for Neuroblastoma Earns Rare Pediatric Disease Designation

According to a story from BioSpace, the radiopharmaceutical company Clarity Pharmaceuticals has recently announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to its…

Continue Reading Experimental Treatment for Neuroblastoma Earns Rare Pediatric Disease Designation
The Only Oral Drug for AIDS-Related Kaposi Sarcoma Has Been FDA Approved
source: pixabay.com

The Only Oral Drug for AIDS-Related Kaposi Sarcoma Has Been FDA Approved

  According to a recent article in Medscape, the FDA has issued accelerated approval for Bristol-Myers Squibb's Pomalyst (pomalidomide). Pomalyst was approved as the first new oral treatment for AIDS-related…

Continue Reading The Only Oral Drug for AIDS-Related Kaposi Sarcoma Has Been FDA Approved
Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
source: pixabay.com

Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.

  In a recent article that appeared in Science Magazine, Amy Boland described her twelve-year quest to find a cure for the cancer that invaded her lymph system. At first,…

Continue Reading Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
source: pixabay.com

Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.

  In a recent article that appeared in Science Magazine, Amy Boland described her twelve-year quest to find a cure for the cancer that invaded her lymph system. At first,…

Continue Reading Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation
source: pixabay.com

Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation

Immune-Onc Therapeutics recently received clearance from the FDA to begin trials of IO-202, a treatment for acute myeloid leukemia (AML). This news comes after the cancer immunotherapy company filed an…

Continue Reading Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation
The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis
Elizabeth M. Dugan, Adam M. Huber, Frederick W. Miller, Lisa G. Rider / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis

  This year, because of COVID-19, many healthcare-related events and symposiums have been moved online. However, that doesn't mean that the insights are any less helpful! In the virtual ACR…

Continue Reading The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis
A Negative Side Effect of COVID-19: Reduced Cancer Screenings
Photo by National Cancer Institute on Unsplash

A Negative Side Effect of COVID-19: Reduced Cancer Screenings

In her early 20's, Mackenzie Alleman lost her mother to breast cancer. Then, at 28, she herself underwent a preventative double mastectomy after learning that she carried the mutated BRCA1 gene.…

Continue Reading A Negative Side Effect of COVID-19: Reduced Cancer Screenings
UCSF Scientists Use Genes as an On/Off Switch to Fight Autoimmune Diseases and Cancer
source: pixabay.com

UCSF Scientists Use Genes as an On/Off Switch to Fight Autoimmune Diseases and Cancer

  Immunotherapies are in the forefront for treating autoimmune diseases and cancer. Northwestern University and the University of California San Francisco conducted a study using genes that have the potential…

Continue Reading UCSF Scientists Use Genes as an On/Off Switch to Fight Autoimmune Diseases and Cancer
Close Menu